Overall, our data unveil that the NRG1β/ERBB3/ERRB2 axis promotes cell growth in suspension of basal-like/triple-negative breast cancer cells and that this process is efficiently prevented by the administration of anti-ERBB2 agents, in particular, pertuzumab. This evidence concerns the gene ERBB3 and triple-negative breast carcinoma.